Ftse Mib
34.815,91
0,00%
DAX
18.742,22
-0,08%
S&P 500
5.221,42
-0,02%
NASDAQ
16.388,24
0,29%
Bitcoin
62.621,83
-0,45%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Amarin Corp PLC (AMRN) Amarin Corp PLC (AMRN) Notizie

AMRN

Amarin (AMRN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AMRN
DataOraFonteTitoloSimboloCompagnia
06/05/202414:00GlobeNewswire Inc.Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor ConferenceNASDAQ:AMRNAmarin Corp PLC
01/05/202413:00GlobeNewswire Inc. Amarin Reports First Quarter 2024 Business Update and Financial ResultsNASDAQ:AMRNAmarin Corp PLC
24/04/202420:00GlobeNewswire Inc.Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular EventNASDAQ:AMRNAmarin Corp PLC
22/04/202414:00GlobeNewswire Inc.Amarin Announces Results of Annual General Meeting of ShareholdersNASDAQ:AMRNAmarin Corp PLC
15/04/202414:00GlobeNewswire Inc.Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024NASDAQ:AMRNAmarin Corp PLC
08/04/202414:00GlobeNewswire Inc.Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24NASDAQ:AMRNAmarin Corp PLC
08/04/202412:30PR Newswire (Canada)New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient SubgroupsNASDAQ:AMRNAmarin Corp PLC
06/04/202421:30GlobeNewswire Inc.New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient SubgroupsNASDAQ:AMRNAmarin Corp PLC
03/04/202414:00GlobeNewswire Inc.Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in EuropeNASDAQ:AMRNAmarin Corp PLC
25/03/202413:00GlobeNewswire Inc.Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & ExpoNASDAQ:AMRNAmarin Corp PLC
04/03/202423:30Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:AMRNAmarin Corp PLC
04/03/202414:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:AMRNAmarin Corp PLC
29/02/202413:06Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AMRNAmarin Corp PLC
29/02/202413:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMRNAmarin Corp PLC
29/02/202413:00GlobeNewswire Inc.Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:AMRNAmarin Corp PLC
15/02/202414:00GlobeNewswire Inc.Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024NASDAQ:AMRNAmarin Corp PLC
12/02/202414:00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:AMRNAmarin Corp PLC
09/02/202422:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRNAmarin Corp PLC
22/01/202413:30GlobeNewswire Inc.Amarin Chairman & CEO Issue Letter to ShareholdersNASDAQ:AMRNAmarin Corp PLC
10/01/202413:00GlobeNewswire Inc.Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024NASDAQ:AMRNAmarin Corp PLC
12/12/202322:20Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AMRNAmarin Corp PLC
11/12/202314:00GlobeNewswire Inc.Amarin to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:AMRNAmarin Corp PLC
05/12/202313:30Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:AMRNAmarin Corp PLC
12/11/202315:00GlobeNewswire Inc.New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at BaselineNASDAQ:AMRNAmarin Corp PLC
01/11/202312:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AMRNAmarin Corp PLC
01/11/202312:00GlobeNewswire Inc.Amarin Reports Third Quarter 2023 Financial ResultsNASDAQ:AMRNAmarin Corp PLC
31/10/202317:00GlobeNewswire Inc.Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance OfficerNASDAQ:AMRNAmarin Corp PLC
26/10/202314:00GlobeNewswire Inc.Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023NASDAQ:AMRNAmarin Corp PLC
19/10/202314:00GlobeNewswire Inc. Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023NASDAQ:AMRNAmarin Corp PLC
12/09/202314:00GlobeNewswire Inc.Amarin to Present at the 2023 Cantor Global Healthcare ConferenceNASDAQ:AMRNAmarin Corp PLC
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AMRN

La tua Cronologia

BIT
11COV
Covestro
BIT
18TRA
Traton
BIT
19MW
Marvell Technology
BIT
1A
Agilent Technologies
BIT
1AA
Alcoa
BIT
1AAD
Amadeus Fire
BIT
1AAG
Aumann
BIT
1AAL
American Airlines
BIT
1AAPL
Apple
BIT
1ABBV
Abbvie
BIT
1ABI
Anheuser Busch InBev SA NV
BIT
1ABNB
Airbnb
BIT
1ACA
Credit Agricole
BIT
1ACS
ACS Actividades de Const...
BIT
1AD
Koninklijke Ahold Delhai...
BIT
1ADBE
Adobe
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network